Human T-lymphotropic virus: Exposure and prognosis by Soskolne, C.L. et al.
pression was made and appropri-
ate therapy begun. He persisted
in his delusions until a test for
antibody to human T-lympho-
tropic virus type III yielded nega-
tive results. He then agreed that
his symptoms could have been
caused by depression. He recov-
ered slowly.
This case and others illus-
trate how the fear of AIDS can
cause symptoms paralleling those
of the syndrome. Miller and
Green2 succinctly described how
to counsel patients with fear of
AIDS. As physicians we must
keep up to date with the explo-
sion of information about AIDS
and be prepared to take the time
to reassure our patients about
their concerns and fears. In this
way we may be able to allay the
hysteria that has been fuelled by
some media coverage of this phe-
nomenon.
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TX . he separation of risk fac-
tors for exposure from co-
factors in prognosis is im-
portant at all levels of preven-
tion. The recent CMAJ articles
from the Vancouver Lympha-
denopathy-AIDS Study group,1-5
and in particular the last article,
by Schechter and colleagues,5
contribute to our understanding
of factors determining exposure
to the so-called human T-lym-
photropic virus type III (HThV-
III) and prognosis.
Schechter and colleagues,
however, draw conclusions from
their data in the last article that
in our opinion are not justified
on the basis of the data they
present. Specifically, in obtaining
the initial results from their co-
hort the authors used a cross-sec-
tional study design, postulating a
hypothesis that could be tested
only after adequate serial follow-
up of their cohort, probably by
way of a nested case-control de-
sign. The authors conclude that
their "data do not support the
hypothesis that further immuno-
logic dysfunction arises from re-
peated exposure to the virus after
seroconversion". We urge caution
in this interpretation: although it
may be correct, the cross-section-
al perspective presented in their
paper is not appropriate to ad-
dressing such a hypothesis.
We offer three explanations
for the finding that the number
of male sexual partners has no
apparent effect on the absolute
number of helper T cells when
HTLV-III antibody status is
taken into account.
* The data derive from an
initial cross-sectional view of a
study population. Given the very
recent advent of a sexually trans-
missible (slow) viral agent in the
Vancouver homosexual study
population, prospective follow-
up will be essential to validate
this observation.
* Most of the lifetime sexu-
al partners could have been en-
countered before the advent of
the virus or could have been
uninfected; the impact of infec-
tion on T-cell numbers must be
observed prospectively.
* The reported lack of a
statistically significant change in
the mean number of helper T
cells with an increase in the
number of partners over the pre-
vious year may have been due
more to a lack of statistical power
than to a true lack of increase.
However, the suggested trend to-
ward an increase could have been
due to any combination of sever-
al potential influences: the cut-
offs selected for categorization
purposes, the implicit assump-
tions of a linear relation among
the three categories, a temporary
T-cell response to recent expo-
sure, sexual practices that are un-
related to the risk of virus trans-
mission, and differing age distri-
butions among the categories
(which also may be related to
sexual practices). The data con-
trolling such potential confound-
ing variables should be reana-
lysed in an attempt to support
the findings reported. This could
be done on an enhanced sample
with a logistic regression model
so that continuous rather than
categorized data could be used
and so that a number of variables
could be included simultaneous-
ly.
Inferences made throughout
the last article about effects on
persistent generalized lym-
phadenopathy and acquired im-
mune deficiency syndrome
(AIDS) would be more appropri-
ate only after adequate follow-up
of the cohort. Schechter and col-
leagues state that viral infection
"may be a cofactor in accelerating
immune dysfunction in HTLV-
III-infected patients". This state-
ment is supported by the data
from both seronegative and sero-
positive men. However, any sug-
gestion that AIDS-associated
clinical manifestations are related
to virus exposure cannot be sub-
stantiated from the data present-
ed. The study was of cross-sec-
tional design and showed the re-
lation between seroconversion
and T-cell counts; it showed no
relation with more severe clinical
or end-stage manifestations of
HTLV-III infection.
Finally, reporting the results
of only the first 219 HTLV-III
antibody tests and T-cell counts
may have introduced some classi-
fication bias. The authors do not
explain the nature of the 219
subjects, especially relative to the
subjects of the preceding reports
in the series, whose numbers var-
ied. The demand for testing by
the only facility in Canada to
have been conducting these tests
is known to have been so great
that delays of 8 months or more
could have occurred. Could the
testing of variously reactive sam-
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ples (particularly the subset sub-
mitted for confirmation testing)
have been delayed beyond the
data analysis stage? Exclusion of
such samples from the data set
could have introduced a classifi-
cation bias, particularly if the
degree of reactivity is in any way
related to T-cell dysfunction.
Comparison of the 219 subjects
of the last report with the sample
complement for patient charac-
teristics and proportional anti-
body reactivity would help to
address such concerns.
We look forward to the pro-
spective analyses from the Van-
couver study.
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[Dr. Schechter and colleagues re-
ply:]
We thank Dr. Soskolne and co-
workers for their thoughtful
comments on the articles from
the Vancouver Lymphadenopa-
thy-AIDS study. In many in-
stances, the cautions they raise
are those that we stressed in our
articles, and their correspondence
can only help to reinforce these
messages.
We confess some uncertain-
ty as to how one goes about
properly "addressing" a hypothe-
sis. We are familiar, however,
with how one might generate a
hypothesis and how one might
test it. We did say in our last
article that our study was "clearly
a hypothesis-generating investi-
gation". Our colleagues know, as
we do, that many tens of thou-
sands of Canadians are already
infected with HTLV-III, and
many more are being infected
every day. In hundreds, and per-
haps thousands, of these people
AIDS is in the process of devel-
oping by virtue of mechanisms
we do not understand, and medi-
cal science has nothing to offer
these people to alter this process.
It is imperative to generate hy-
potheses about the pathogenesis
of AIDS as expeditiously as pos-
sible; these hypotheses can then
be tested epidemiologically and
by using techniques of im-
munology and molecular biology.
To ignore the extensive amount
of data we have been fortunate
enough to accumulate would be
not only unjustifiable but also a
disservice to the many thousands
of infected people and to the
public.
Hypotheses generated in this
type of investigation must be
interpreted with caution (as we
urged), must be tested prospec-
tively (as we pointed out) and
must always be considered in the
light of pre-existing evidence.
The data we presented concern-
ing viral cofactors, and our inter-
pretation of these data, were en-
tirely consistent with those from
many other investigations re-
viewed in our discussion. Recent-
ly Laure and associates' have de-
tected hepatitis B virus DNA in-
tegrated in the DNA of lympho-
cytes of AIDS patients, which
provides corroborative evidence
of a role for hepatitis B as a
cofactor. As for our data on the
role of repeated exposure, we
concluded that they "do not sup-
port the hypothesis that further
immunologic dysfunction arises
from repeated exposure to the
virus after seroconversion".
However, we pointed out that our
data agree entirely with those of
Goedert and collaborators,2 the
only other investigators to have
carried out a similar analysis. In
general, data either do or do not
support a hypothesis. Since the
former was not true, the latter
must then hold. Surely this can-
not be considered an overinter-
pretation.
Soskolne and coworkers
have kindly supplied three expla-
nations for our finding that the
number of male sexual partners
has no apparent effect on the
absolute number of helper T cells
when HTLV-III antibody status
is taken into account. The first
suggestion is that the AIDS virus
has only recently appeared and is
"slow"; we may have yet to see
its results. However, our data in
the second article, which showed
significantly decreased helper T-
cell counts in seropositive as
compared with seronegative men,
demonstrate that however recent
and slow this virus is, its effects
on our study population have
already been pronounced.
The second explanation con-
cerns changes in behaviour be-
fore and after the advent of the
virus that are clearly dealt with
in our discussion. We noted no
effect on helper T-cell counts in
seropositive men with an elevat-
ed number of sexual partners in
the year preceding enrolment or
with any other exposure factor.
Moreover, the suggestion by Sos-
kolne and coworkers that most of
the lifetime sexual contacts could
have occurred before the advent
of the virus, or with uninfected
people, is not consistent with our
observation that an elevated life-
time number of sexual partners
was a significant independent
risk factor for seropositivity at
the time of entry into our study.
As their third explanation
Soskolne and coworkers suggest
that the reported lack of a statis-
tically significant increase in the
mean number of helper T cells
may have been due to a lack of
statistical power rather than a
lack of a true increase. There is,
of course, always the possibility
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